FDA Inspection 1141793 — Arevipharma GmbH
The FDA completed an inspection of Arevipharma GmbH on September 16, 2019 in Radebeul. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 16, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Radebeul (Germany)
Additional Details
Mutual Recognition Agreement (MRA)